Evidence map›Paper›PMID 42689273›Full record

ArticleFrontiers in pharmacology2026

Tissue-specific untargeted

M V Masiphephethu, S Bhengu, K Venter, Y Lemmer, S Mason

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

M V MasiphephethuBiomedical and Molecular Metabolism (BioMMet) Research Group, Faculty of Natural and Agricultural Sciences, North-West University, Potchefstroom, South Africa.
S BhenguBiomedical and Molecular Metabolism (BioMMet) Research Group, Faculty of Natural and Agricultural Sciences, North-West University, Potchefstroom, South Africa.
K VenterPreclinical Drug Development Platform, Faculty of Health Sciences, North-West University, Potchefstroom, South Africa.
Y LemmerPreclinical Drug Development Platform, Faculty of Health Sciences, North-West University, Potchefstroom, South Africa.
S MasonBiomedical and Molecular Metabolism (BioMMet) Research Group, Faculty of Natural and Agricultural Sciences, North-West University, Potchefstroom, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cannabidiol (CBD) has attracted renewed scientific attention for its therapeutic potential in human metabolism. However, the metabolic effects of CBD treatment remain incompletely understood. Methods: This study investigated tissue-specific metabolic alterations in the brain, liver, and kidneys of Kramnik mice after 2 weeks of daily CBD treatment using an untargeted proton magnetic resonance ( Results: Unsupervised principal component analysis (PCA) revealed minimal biological variation between the CBD-treated and control groups. The most notable, albeit minor, changes were observed in the brain and were associated with decreased signaling and neuroenergetics. The liver showed changes in sugar metabolism, and the kidneys showed only minor changes in phenylalanine levels. Discussion: Collectively, our results suggest a more metabolically balanced state in the mice. These data support the adjunctive use of CBD, as no adverse metabolic effects were observed in the brain, liver, or kidneys.

Indexed as

braincannabidiol (CBD)kidneyslivermetabolismmiceproton magnetic resonance (1H-NMR)untargeted metabolomics

Identifiers

PMID42689273
PMCPMC13537750

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.